title: Tetracationic porphyrins inhibit angiogenesis induced by human tumor cells in vivo.
abstract: BACKGROUND
  Cationic porphyrin TMPyP4, but not its isomer TMPyP2, inhibits telomerase in tumor cells in vitro and induces chromosome destabilization in vivo.
  
  
  METHODS
  To examine the effects of these porphyrins on tumor-induced angiogenesis, 25-200 micrograms TMPyP4 or TMPyP2 were injected daily for 3 days in mice with intradermally implanted primary human tumor cells. Alternatively, tumor cells were exposed for 90 minutes to 2.5-20 microM porphyrins prior to implantation in mice.
  
  
  RESULTS
  Either subcutaneous injections (> or = 50 micrograms/mouse) or preincubation with > or = 5 microM porphyrins significantly inhibited angiogenesis.
  
  
  CONCLUSIONS
  Antiangiogenic activity is apparently unrelated to the ability of the porphyrins to inhibit telomerase.
authors.affiliation: Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA. eizbicka@saci.org
authors.forename: E
authors.initials: E
authors.lastname: Izbicka
authors.forename: E
authors.initials: E
authors.lastname: Sommer
authors.forename: E
authors.initials: E
authors.lastname: Skopinska-Rozewska
authors.forename: K
authors.initials: K
authors.lastname: Davidson
authors.forename: R S
authors.initials: RS
authors.lastname: Wu
authors.forename: T
authors.initials: T
authors.lastname: Orlowski
authors.forename: K
authors.initials: K
authors.lastname: Pastewka
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000098:blood supply / Q000473:pathology; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D018288:Carcinoma, Small Cell / Q000098:blood supply / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000098:blood supply / Q000473:pathology; D002295:Carcinoma, Transitional Cell / Q000098:blood supply / Q000473:pathology; D016228:Endothelial Growth Factors / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000473:pathology; D008175:Lung Neoplasms / Q000098:blood supply / Q000473:pathology; D008222:Lymphokines / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009389:Neovascularization, Pathologic; D010894:Piroxicam / Q000494:pharmacology; D011166:Porphyrins / Q000008:administration & dosage / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000098:blood supply / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D020533:Angiogenesis Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016228:Endothelial Growth Factors; D008222:Lymphokines; D011166:Porphyrins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D010894:Piroxicam; C021096:tetra(4-N-methylpyridyl)porphine; C057456:tetra(2-N-methylpyridyl)porphine; D001241:Aspirin